Can N-acetylcysteine preserve peritoneal function and morphology in encapsulating peritoneal sclerosis?

Area of Science:

• Nephrology
• Biomedical Engineering
• Pharmacology

Background:

• Long-term peritoneal dialysis can cause irreversible dysfunction and fibrosis.
• Oxidative stress from dialysis solutions, including reactive oxygen species (ROS), contributes to membrane damage.
• N-acetylcysteine (NAC) is an antioxidant known to scavenge ROS.

Purpose of the Study:

• To investigate the effects of NAC therapy on the progression and regression of encapsulating peritoneal sclerosis (EPS).
• To evaluate NAC's efficacy compared to peritoneal rest in a rat model of peritoneal injury.

Main Methods:

• 49 rats were divided into control, chlorhexidine gluconate (CG) induced injury, resting, and NAC-treated groups.
• Animals received daily intraperitoneal injections for 3 weeks, followed by a 3-week treatment period (rest or NAC).
• Peritoneal function was assessed using a peritoneal equilibration test, measuring D/P urea, white blood cell count, and ultrafiltration volume.

Main Results:

• CG-induced injury led to EPS, characterized by ultrafiltration loss, increased peritoneal thickness, inflammation, and fibrosis.
• Peritoneal rest improved dialysate cell count.
• NAC therapy decreased inflammation and vascularity, showing greater efficacy than rest in these aspects, but did not benefit fibrosis.

Conclusions:

• NAC therapy demonstrated potential in protecting the peritoneal membrane by reducing inflammation and vascularity in a severe injury model.
• While NAC did not prevent fibrosis in this model, its anti-inflammatory and anti-vascular effects are promising for peritoneal dialysis membrane protection.
• Further research may be needed to explore NAC's role in mitigating fibrosis in less severe injury models.